Mannkind Corp Investor Event Transcript, Nov 18, 2026
Mannkind Corp (MNKD)
Mannkind expects Q4 revenue of about $38 million, plus or minus. Natetanib DPI moves toward Phase 2 in the U.S. after FDA feedback. AI summary
Conference Transcript - MNKD 2026-11-18
Operator
Good morning, and welcome to Jeffrey's 2026 Global Health Conference. It's my pleasure to now introduce the CEO of Mankind.
Michael E. Castagna, CEO
Good morning, everybody. Thanks for joining us today. So, looking at mankind, as we go forward in 27, we have three major engines for growth. Number one is growing our commercial revenue with Furosix Freddy Floats off to a very strong start. Our Fraser Pediatrics has shown some nice early adoption here with one out of three pediatric endocrinologists writing the product already. And then expanding our UT collaboration in terms of executing Tybasa DPI and getting ready for their next Phase III trial for IPF and hopefully PPF. And in Verlanipeg, which could be a great once-a-day prostacycline, here we expect about $15 million a milestone from our relationship with UT as well as clinical supply revenue, et cetera. And finally, we look at the long-term, our natetanib DPI, which is our entry into the IPF space. We'll be moving into phase two here in the U.S. very shortly, as well as global, into a large trial with about 150 patients, as I'll talk about. As you look at mankind, it's been a very quick journey over the last five years since COVID. We've had a 42% CAGR that's been built between royalties, inline commercial collaboration revenue, as well as two inline growth drivers with 306 and Afreza. We expect to be profitable here in Q4, and we'll have record revenues as well. As you look out, a lot of people want to have some exposure to IPF space. We have three shots on goal with IPF between Relenopeg, Tivasa DPI, as well as Netetnib. In Q3... Our furosic variety flow received approval. About 75% of the furosic shipments have converted already. We continue to see strong momentum here as we close out November. Our Fresa Pediatric launch is up 80% in terms of new-to-brand prescriptions. We've increased our market share significantly over adult already. And we have positive Phase 1B inflow results, which was around the IPF trial showing tolerability in IPF patients. That trial has now been the foundation with the FDA to advance into Phase 2 here in the U.S. as well as the rest of the world. And we were able to bring in a high-quality life science investor with Frazier here as we closed out a $45 million milestone here when we got the ready flow approval here back in August. As we look at 306, this came to mankind through the acquisition of SC Pharma. We look at the market in terms of four major segments. The first segment, worsening at home, is where 90% of our sales come today, and these are patients who are going to move towards the hospital, trying to prevent them from even going into the ER and ultimately into the hospital. Then you get into the second part, which around emergency department, that's going to be the hardest segment to penetrate because you have a lot of complexities in an ER system to capture these patients. The third segment is really around in the hospital and IV diuretics, and this is where we see the next big opportunity as we go forward in terms of getting people at discharge and really working on the last segment here being post-discharge readmission. Each of these segments are almost a million patients a year, and they're combined. I mean, so if you add them all up, it's a very large opportunity here to either prevent hospitalization, get people out of the hospital early, or prevent them from going back to the hospital. What we find is that as somebody starts to adopt the furosics on this journey, they start to identify the other segments naturally, and that's what's really nice. We've got to find a leader in a health system, and usually it's going to be either worsening at home or the post-discharge, and then they start to really identify with their colleagues how else can they be using this to really help make a dramatic change in their health system. This is the first and only IV equivalent diuretic. It works in under 10 seconds. We weren't sure how the on-body infuser would be. It would just be a three, four-quarter conversion. We saw with the launches in the first 30 days, very high-rated conversion. 90% of our community's prescriptions coming in for demand are for the ready flow already. The hospital segment, we slowed down a little bit. We'll be opening that up this week, and you'll continue to see the hospital segment grow and catch up. For those who know what furosics is, it's really to treat fluid overload in a CKD and hospital setting and really get people leaving the hospital hopefully earlier is the big opportunity. So as you look at the strong demand here, the four weeks ending 9-6, which is right before launch, you can see 100% of our share was OBI, the all-body infuser. And then within four weeks, we saw 56%, and in the other four weeks, 73%. This has only continued to move in the right direction. Greater than 50% average shipment doses, so we're seeing nice. We had new highs last week in terms of referrals. Despite a co-pilot outbreak, an airline shutting down, we still had record referrals last week, so we were happy. Our shipments continue to be strong. Our new riders continue to be strong. And about two out of three patients are new to brand. So these are really our new to patients, new prescribers, coming in for the first time to 306. I'm going to bridge over to AFRESA. For those of you who don't know Mankind, we were founded really on the history of AFRESA here, and we've been waiting a long time to get the pediatric approval. This was for several reasons. One, the overhang of inhaled insulin was around safety, and we thought getting approval for children would signify the safety side of this equation. We also had to fix some dosing opportunities. The drug, when it was originally approved, was underdosed by about 50%. That also got changed this year along with the pediatric approval. So two major changes in AFRESA as we go forward. And when you think about what we saw here is, you know, we took our eye off the ball a little bit in the adult segment as we integrated SC with 306. We increased the share of voice on 306 to make sure we had that go into a nice trajectory. That, that... What we saw was that the brands are promotion responsive, right? If we put more energy on nephrology, it grew faster. We took the eye off the ball on adult. And so as we go into 2027, we're going to actually double down on adult and put the sales force back focus there, as well as increase the cardiovascular footprint to have more reach and frequency against the nephrology as well as cardiology segments. So as we go into next year, we'll continue to see this become a growth inflection, where this year we had a little bit of softness in adult combined with the PEDSWONT launch. We saw some growth here in Q3 from Q2, and about one in four patients here as we ended the quarter were pediatric, so we really see a nice uptake here in a very short amount of time. This is our market share from launch, and you can really see how peds, 2x adults here in the first 90 days of launch, you can see the new to brand, you can see the pediatric patient here, really, really showing a nice trajectory and a nice adoption here. And now what we've got to do is get the repeat opportunity and the depth of prescribing. But what we're seeing now is that patients are starting to come back, the refills are starting to build, and we're seeing really good refill rates on children as well. So we're very happy with the early signs here for pediatrics. As you think about mankind and lung-targeted delivery, this is an area that was the foundation of the company. Making inhaled therapies is one of the hardest things to scale. I did appreciate it as a pharmacist coming into the company 10 years ago. It really is a unique platform, and the chart on the left here really shows you getting this inhalation, slowing the powders down, getting deep lung deposition consistently across is something that is really critical to delivering dose-to-dose consistency, and we see that in our Taveso DPI as you scale up. The dose continues to go linear. The same thing in Afreza, you can add two cartridges to get 8 and 8, 16. Not most dry powders can have that much direct accuracy of addition, and that really has been a proven platform here. Practical administration in under two seconds, you can inhale. You don't have to clean the device, you can throw out the device, and that really has given patients a great experience, and we've seen really good tolerability in thousands of patients now in terms of cough and how that improves over time. As I mentioned in my opening, we have three opportunities in the near term. We are happy to see United Therapeutics moving this forward in terms of our blockbuster that we work with them on is Typeso DPI. They've done an amazing job. This is off to a great start here. You can see its return back to growth in Q3, and we expect to continue success here in Q4 and beyond. They'll be expanding into IPF and PPF in the future, and we'll continue to be there to support UT to move as fast as we can. On the tetanib, this has been our own molecule. We started this probably seven years ago. These things take a long time, unfortunately, but we're moving finally in the right direction. We're really excited. We had a great meeting with the FDA, and I'll share some of that discussion in a minute. And then Relenepeg, which is something UT has really been pushing hard this year. This is a once-a-day super prostacycline, really multi-indication potential from pH to PHILD to IPF and PPF. Relenepeg oral tablets should get approved hopefully in 27, and this will be a nice expansion into the IPF and PPF space. So we have a long-term roadmap here working together with our partner as well as our independents, and we're excited. When you look at the UT collaboration, we've built out manufacturing capacity expansion to really support up to 250,000 patients. When we look at how big this market can be, the unmet need, the multiple products that we're working on, they've built a second plant there in North Carolina to support Relenopeg, and we'll be the primary manufacturers here for Tyveso. So this is going to provide a durable economic background for the company for years to come, and whether that's going to be Tyveso or Relenopeg, we're really proud of the work we're doing and proud of our partnership with United Therapeutics. This shows you, you know, Teveso was a great tailwind. When we look at the DPI sales, it was really helping us over the last couple of years. And then the last year kind of became flat, and then it was a headwind, and mankind started growing our own portfolio faster. And you can see here in Q3, it really returned to great growth here quarter over quarter. And everything we're hearing in Q4 should look good, hopefully, from all the presentations we heard from UT. We'll be the sole source of manufacturing for Teveso. That was a big shift this year. We had thought they were going to move it to manufacturing to North Carolina. So our manufacturing revenue and our manufacturing capacity will continue to be supported here with UT over the coming years. And we expect about $1 billion in revenue between manufacturing and royalties between now and 2030. So we see this bringing in a nice, consistent, and steady revenue stream. As we get into the 2030s, we'll start to see Relent-A-Peg and other products moving forward here. This is our lieutenant DPI. It's exciting to see it finally come to fruition. We've built three programs on top of the chronic toxin and some of the animal modeling, and you can see here, you know, first in human was great in a phase 1A. That was completed almost two years ago now, and then we did 1B in July of 26. We just released those results, and you can see in 27 IPF patients, we had no discontinuations. People really tolerated the product, and then phase 2, inflow 2 here, that's really going off. We just met with the FDA. We'll add about 15 sites here in the U.S., so this will get to about 100 sites, about 153 patients. We'll evaluate, you know, is there anything else we should be doing in Phase 2 that would count this as one of the trials potentially for approval? But so far, we got really good, clear feedback with the FDA, and we plan to move this forward here in the U.S. That was one of the unknown questions we had coming into this week that we can clarify now, so we're excited to bring it there. The doctors are excited, and we'll be activating sites as quickly as possible. A lot of questions on can a patient with IPF tolerate our dry powders, and that was a really important question to answer here, not just for us, but also for Tyveso, because in the case of... The tetanib or tyveso, most of the powder is our novel excipient FTKP. We've used this in thousands of patients around the world, and you can really hopefully see that 60% of the patients reported no increase in cough, 30% had a mild cough, which sounds like that's it. And so when you talk to the patients, they don't mind that cough. They're already coughing several times a minute, and they just want something that's going to give them a chance that's tolerable. And we had no discontinuations for cough. And so we look, we had, I think, over 700 doses inhaled over those seven days in this trial with no major issues. And so we're really excited about the tolerability and what we can do between this and the other phase 1A trial. We've had a lot of inhalations, but no major risk of bronchiospasm, no cough discontinuation, no diarrhea, nothing that you see in traditional natetanib. So now our last question here is, will we have some efficacy in phase two? Adding to the U.S., we said we expect the first half of 28. We're hoping by adding to the U.S. we'll pull it up to early 28 from a data readout. Here is the design of inflow 2. So it's really testing what is equivalent to 4 milligrams a day versus 8 milligrams a day. You're giving that in 2 milligrams BID. We think 4 milligrams BID is the preferred dose and the target dose. And so that's what we'll see here in a placebo-controlled trial. We'll really compare 4 milligrams to placebo to 4 milligrams active, as well as 2 milligrams to 2 milligrams. You can see our bet here is on the higher dose. We stacked the statistics really around the higher dose here. And we'll be moving this forward very quickly here. One of the changes, we did resize the trial from 220 down to 153 patients, and that was because we were looking at QID, and we decided that that was no longer in our interest. We really thought twice a day is going to be enough and why add complexity to this population. So that did slow down enrollment a little bit this year because we had to get the new protocols in, get them all approved, and we thought slowing down to go fast was the right strategy here. and getting us more meaningful data in a twice-a-day regimen was important. So this is setting us up for hopefully future combination use as we look at the market. As we look ahead, the future looks very bright. We're really excited about everything going on in the company. You look at our commercial products, they are growing rapidly. Fresa's return to growth now. Ferocious Ready Flow is off to a very strong start. We expect Q4 to be about $38 million in revenue. It'll be plus or minus. Obviously, we're midway through the quarter, and a lot can go into that still. But so far, the demand trends we see, we think it's important to bring clarity to where we're seeing Q4 show up. Afreza Pediatrics, we did double that share. That gave us some confidence to continue to push Afreza next year, really refocus the adult, get that growing, and then support the children and continue to expand. We'll also be bringing out a low-dose cartridge next year, which will be a two-unit cartridge, and then some digital technology connecting the inhaler to CGM. When you look at the expanding Unithir collaboration, there was a lot of noise in the beginning of this year, kicking off the year, that questioned whether this was going to be a durable revenue stream. We feel very confident going forward this will be a very durable revenue stream. Taveso will continue to go strong. We'll be the sole source manufacturer. That will continue to be a good revenue stream. And just supporting the factory as it makes 201, it makes Afreza, and other things we're moving forward. As we know, IPF has been littered with failure across the U.S. and the world. It's a really tough disease, and we think this is a population who still deserves new treatments, and we're excited about helping those patients and moving our Netentenib forward. So when you look here, and some milestones here, we have natetanib going hopefully quicker in enrollment. You have a FREZA inhale first, which is the very first dose a newly diagnosed child will receive inhaled insulin. So they come out of the hospital hopefully within 10 days, and they'll start inhaled insulin. And that's how you break the pump mindset that's there today. We're doing this in 10 of the top centers in the U.S. Experience so far just got presented two weeks ago, and the first 10 or 12 patients looked excellent. And there are about 35 patients now in this trial. Our goal is to get to 100 patients by mid-next year and have a data readout. It's a 12-week endpoint. Relenopeg is advancing there. We'll continue to watch how that goes as we kick off January. Two-unit cartridge is something that the market has asked for 10 years. They really want that fine-tuned dosing. We think there's an opportunity, especially with the newly diagnosed kids who are in the honeymoon period, but one, smaller doses, we see that. We're using that dose in the inhale-first trial. We are seeing that widely used. Inhale IQ is something we've been working on for a long time. It's finally ready to go. We are submitting that to the FDA, and hopefully that will be our product launch next year. And what that is, it's an adapter on the inhaler that will read the cartridge you took. It will integrate that with CGM. It will be a data report you can share with your doctor, and as a parent, you can see it. And if you, you know, question, did your babysitter give a dose? Did they get the dose in the school? These are all the questions you get around Afreza, and so with a pump, you can see it. You can track the dosing. This will really enable that tracking. In 20 and beyond, we expect a 40-milligram furosic. That will be filed next year. A fresa high concentration, which really opens up the type 2 market. When you think about all the data we generate in type 2s, they really need 16 to 20 units a meal. We'll be able to get that into one inhalation. The other reason that's important is a 12-unit cartridge becomes the same amount of powder as an 8, and an 8 becomes a 4. So just the amount of powder a patient has to inhale only gets better with time as we bring these new formulations out. And then we expect a day to read out here, hopefully early in the first half of 28. That's it for Mankind. I'll open up to any questions. Well then, thank you for your time. I look forward to seeing all of you in the future. Have a great day.